select trial semaglutide cardiovascular outcomes non-diabetic 2023 and in patients with obesity and prevalent heart failure: a prespecified analysis of the GLP-1 medications are rewriting the

As a rheumatologist with years of experience treating patients with autoimmune conditions, Ive seen firsthand the challenges that come with managing diseases like rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA)

The researchers said in a news release that even after they adjusted for age, body mass index, disease severity and other health factors, GLP-1 users still had far lower odds of death, suggesting a strong and independent protective effect. The survival effect was highest in those with BMI above 35, suggesting the drugs could help counteract inflammatory and metabolic challenges that worsen colon cancer prognosis

Until more robust evidence emerges, clinical decisions must be individualised, weighing the theoretical risks of reduced absorption against the patient's preferences, diabetes control, and alternative treatment options

Close supervision by a skilled healthcare provider helps to mitigate these potential risks